🟢 Definium Therapeutics, Inc. is trading 52.6% up today after positive Phase 3 Emerge results for DT120 ODT

Definium Therapeutics, Inc. is trading at $37.35 (+52.57%) after announcing positive topline Phase 3 Emerge results for DT120 ODT in major depressive disorder.

• The study met its primary endpoint and all key secondary efficacy endpoints, providing a clear company-specific catalyst for the stock's significant move.
• The stock saw increased event-driven attention ahead of a June 22 webcast scheduled to discuss the clinical data.
• Current trading volume and price action indicate a strong market reaction to the clinical readout rather than broader market sentiment.